证券代码：832566 证券简称：梓橦宫 公告编号：2024-036 四川梓橦宫药业股份有限公司董事会财务与审计委员会 对会计师事务所履行监督职责情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等有关规定和要求，四 川梓橦宫药业股份有限公司（以下简称"公司"）董事会财务与审计委员会本着 勤勉尽责的原则，恪尽职守，认真履职，对中汇会计师事务所（特殊普通合伙） （以下简称"中汇会所"）2023 年度审计工作履行了监督职责，现将情况汇报如 下： 一、 会计师事务所基本情况 （一）会计师事务所基本情况 中汇会计师事务所（特殊普通合伙）成立于 2013 年 12 月 19 日，注册地址 为杭州市江干区新业路 8 号华联时代大厦 A 幢 601 室。截至 2023 年 12 月 31 日， 合伙人数量为 103 位，注册会计师人数为 701 人，签署过证券服务业务审计报告 的注册会计师人 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-039 四川梓橦宫药业股份有限公司（以下简称"公司"）因经营发展需要，为确 保有充足的资金，保证公司健康平稳运营，2024 年度公司及子公司拟向金融机 构申请融资授信总额不超过 1.5 亿元人民币的综合授信额度，授信业务范围内的 融资方式包括但不限于流动资金借款、项目贷款、贸易融资、保函及银行承兑汇 票、商业承兑汇票贴现等，在此额度内由公司及子公司根据实际资金需求向金融 机构进行借贷，融资金额与借贷期限以公司与金融机构实际签署的合同为准。公 司董事会授权公司管理层根据实际情况在前述总授信额度内，办理公司及子公司 的融资事宜，并签署有关与各家金融机构发生业务往来的相关各项法律文件。授 信期限自公司 2023 年年度股东大会审议批准之日起至 2024 年年度股东大会召 开之日止，在有效期内，授信额度可循环使用。 四川梓橦宫药业股份有限公司 关于 2024 年向金融机构申请授信额度的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 申请授 ...

四川梓樟宫药业股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 目 录 | 页 次 | | --- | | 一、年度募集资金存放与使用情况鉴证报告 1-2 | | 二、四川梓ٽ官药业股份有限公司关于 2023年度募集资金 | | | | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 年度募集资金存放与使用情况鉴证报告 中汇会 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-029 四川梓橦宫药业股份有限公司 2023 年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 2023 年度，本人作为四川梓橦宫药业股份有限公司（以下简称"公司"）的 独立董事，在任职期间严格按照《公司法》《证券法》《北京证券交易所股票上市 规则（试行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》 等法律法规、规范性文件及公司《公司章程》《独立董事工作制度》等相关规定， 勤勉尽责，积极出席各项会议，认真审议各项提案并提出建议，始终维护全体股 东尤其是中小股东的利益，切实履行了独立董事的责任与义务。现就 2023 年度 履职情况报告如下： 一、出席董事会、股东大会会议的情况 2023 年度，公司共召开了 8 次董事会，7 次股东大会，本人通过现场或网络 方式按时出席会议，没有委托他人出席会议或缺席的情形。认真履行相关审批程 序，独立、客观、审慎地发表意见并行使表决权，对审议的议案均无异议，也无 弃权、反对 ...

关于四川梓幢宫药业股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 录 目 中汇会专[2024]3219号 四川梓權宫药业股份有限公司全体股东: 我们接受委托,审计了四川梓幢宫药业股份有限公司(以下简称梓植宫公 司)2023年度财务报表,并出具了中汇会审[2024]3218号无保留意见的审计报告, 在此基础上对后附的梓樟宫公司管理层编制的《2023年度非经营性资金占用及其他 关联资金往来情况汇总表》(以下简称汇总表)进行了审核。 | 一、非经营性资金占用及其他关联资金往来情况的专项 | 页 次 | | --- | --- | | 审核说明 | 1-2 | 二、非经营性资金占用及其他关联资金往来情况汇总表 3 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-025 四川梓橦宫药业股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席蒋晓风 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序符合《公司法》等有关法律、行政法 规和《公司章程》的相关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《2023 年度监事会工作报告》 1.议案内容： 根据法律法规和《公司章程》的规定，由公司监事会主席汇报监事会 2023 年度工作情况。 1.会议召开时间：2024 年 4 月 2 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 3 月 22 日以书面方式发出 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 2.议案表决结果：同意 3 票； ...

平安证券股份有限公司 关于四川梓橦宫药业股份有限公司 2023 年度募集资金存放和使用情况的专项核查报告 平安证券股份有限公司(以下简称平安证券或保荐机构)作为四川梓橦宫药 业股份有限公司(以下简称梓橦宫或公司)向不特定合格投资者公开发行股票并 在北京证券交易所上市的保荐机构和持续督导机构，对梓橦宫履行持续督导义务。 根据《证券发行上市保荐业务管理办法》《北京证券交易所上市公司持续监管办 法（试行）》《北京证券交易所上市公司持续监管指引第 9 号——募集资金管理》 《北京证券交易所证券发行上市保荐业务管理细则》等有关规定，平安证券及其 指定保荐代表人对梓橦宫 2023 年度（以下简称"本年度"）募集资金存放与使用 情况进行了专项核查，具体情况如下: 一、募集资金基本情况 （一）募集资金金额、资金到位时间 经中国证券监督管理委员会《关于核准四川梓橦宫药业股份有限公司向不特 定合格投资者公开发行股票的批复》（证监许可[2021] 2369 号）核准， 同意公 司向不特定合格投资者公开发行人民币普通股股票 19,000,000 股（含行使超额 配售选择权），每股面值 1.00 元。本次初始发行 16,521,740 ...

四川梓橦宫药业股份有限公司 2023 年度董事会财务与审计委员会履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 四川梓橦宫药业股份有限公司（以下简称"公司"）第三届董事会财务与审 计委员会根据《公司法》《证券法》《上市公司独立董事管理办法》《北京证券交 易所股票上市规则（试行）》和《公司章程》《董事会财务与审计委员会工作细则》 等相关法律法规及公司规章制度的规定和要求，在 2023 年度积极开展工作、勤 勉尽责。现将履职情况汇报如下： 一、 基本情况 公司第三届董事会财务与审计委员会由 3 名董事组成，分别为黄元林、程志 鹏、李云，其中黄元林、程志鹏为独立董事，主任委员（召集人）由会计专业人 士黄元林担任。 根据《上市公司独立董事管理办法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等相关规定，公 司于 2023 年 12 月 28 日召开 2023 年第六次临时股东大会完成第四届董事会换 届选举。第四届董事会由 7 名董事组成，其中 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥408.05 million, a decrease of 7.71% compared to ¥442.16 million in 2022[27]. - The net profit attributable to shareholders for 2023 was approximately ¥102.32 million, showing a slight increase of 0.25% from ¥102.07 million in 2022[27]. - The net profit after deducting non-recurring gains and losses was approximately ¥88.28 million, representing a growth of 12.09% compared to ¥78.76 million in 2022[27]. - The gross profit margin for 2023 was 80.94%, an increase from 79.96% in 2022[27]. - The basic earnings per share for 2023 was ¥0.71, a 1.43% increase from ¥0.70 in 2022[27]. - The company maintained a weighted average return on equity of 14.15% for 2023, down from 15.19% in 2022[27]. - Total assets increased by 4.28% to CNY 878.20 billion from CNY 842.18 billion in 2022[29]. - Total liabilities decreased by 2.09% to CNY 127.60 billion from CNY 130.32 billion in 2022[29]. - Operating cash flow increased by 7.56% to CNY 115.77 million from CNY 107.63 million in 2022[29]. - The company reported a revenue of CNY 408.05 million for 2023, unchanged from the preliminary report[31]. - The company achieved operating revenue of ¥408,049,692.89, a decrease of 7.71% compared to the same period last year[42]. - Net profit attributable to shareholders increased by 0.25% to ¥102,324,161.07, while net profit excluding non-recurring gains and losses grew by 12.09% to ¥88,279,575.36[42]. - The company’s total revenue for 2023 was approximately CNY 408 million, a decrease of 7.71% compared to CNY 442 million in 2022[56]. - The gross profit margin improved to 80.94% in 2023 from 79.96% in 2022[56]. - The net profit for 2023 was CNY 102.24 million, reflecting a slight increase of 0.63% from CNY 101.60 million in 2022[56]. Market Strategy and Development - The company plans to focus on expanding its market presence and enhancing its product development capabilities in the upcoming year[10]. - The company is actively pursuing new product development and technological advancements to strengthen its competitive position in the pharmaceutical industry[10]. - The company is actively expanding its OTC channel and enhancing its online sales system to build an efficient national marketing network[43]. - The company is committed to expanding its product pipeline and improving its pain relief product line through ongoing R&D efforts[43]. - The company plans to enhance its product pipeline and accelerate the launch of new products to maintain steady growth[51]. - The company aims to build a high-quality traditional Chinese medicine service system by 2025, enhancing its capabilities in disease prevention and treatment[50]. - The company is strategically positioning itself in the healthcare sector through investments in mental health and wellness-related businesses[79]. - The company plans to focus on product innovation and market expansion, with a strategic emphasis on digital marketing and e-commerce to drive sales growth[110]. - The company is committed to improving production management capabilities through smart upgrades and lean production practices, aiming to enhance quality and reduce costs[110]. - The company will expand its traditional Chinese medicine supply chain by increasing the scale and quality of herbal medicine cultivation[110]. Research and Development - The company holds 26 invention patents and 99 drug production approvals, focusing on CNS and digestive system drugs[38]. - The company has initiated 3 new R&D projects and holds a total of 84 patent certificates, including 26 invention patents[43]. - The company has five main R&D projects, including original Chinese medicine varieties, classic prescriptions, chemical generics, consistency evaluation of major varieties, and secondary development of exclusive traditional Chinese medicine products[199]. - The R&D team consists of over 50 personnel, including 1 PhD and 5 Master's degree holders, with 44.90% holding professional technical titles[199]. - The company employs a project-based collaborative R&D model, partnering with domestic universities and research institutions to enhance its research capabilities[199]. - The company has initiated three new drug R&D projects at the end of the reporting period, laying the groundwork for its development during the 15th Five-Year Plan[200]. - The company has developed a patented production process for its products, improving stability and reducing production costs[196]. - The company emphasizes the importance of intellectual property protection, focusing on the creation, registration, and safeguarding of patents, trademarks, and trade secrets[196]. Environmental and Social Responsibility - The company has implemented strict environmental protection measures, including wastewater treatment and air quality management, achieving compliance with national standards[102]. - The company has established an emergency response mechanism for environmental pollution incidents, ensuring timely reporting and control of potential hazards[103]. - The company has received recognition for its employee welfare initiatives, including the "Model Workers' Home" award in Sichuan Province[97]. - The company maintains a focus on sustainable development, balancing economic benefits with social and environmental responsibilities[98]. - The company has successfully renewed its pollution discharge permits, demonstrating ongoing compliance with environmental regulations[100]. - The company actively responds to the national "Rural Revitalization" strategy by establishing a traditional Chinese medicine planting experimental base, contributing to local employment and income increase[96]. Corporate Governance and Management - The company has engaged Zhonghui Certified Public Accountants for its audit, receiving a standard unqualified opinion on its financial statements[10]. - The company has established a robust internal control system for revenue recognition to mitigate risks associated with improper revenue reporting[92]. - The company has engaged Zhonghui CPA as its external auditor for the 2023 annual audit, ensuring compliance with auditing standards[94]. - The company has implemented a stock incentive plan, granting 2.4 million restricted shares at a price of 3.21 yuan per share to 36 individuals[129]. - The company has repurchased 3 million shares using its own funds for the stock incentive plan, with a maximum repurchase price set at 9.00 yuan per share[130]. - The company has a total of 7 directors, 3 supervisors, and 4 senior management personnel[161]. - The company’s management remuneration is determined based on operational scale and industry salary levels[165]. - The company has focused on talent acquisition through various recruitment channels, including university graduates and social recruitment[171]. - The company conducted diverse training activities to improve employee professional skills, laying a solid foundation for future development[171]. Compliance and Risk Management - The company emphasizes compliance and risk management, aiming to establish a long-term risk prevention mechanism to protect investor interests[111]. - The company has implemented measures to control the quality of traditional Chinese medicinal materials from the source, including the establishment of a planting base[114]. - The company has not experienced any significant changes in major risks during the reporting period[115]. - The company has not faced any major litigation or arbitration matters during the reporting period[119]. Shareholder and Investor Relations - The company emphasizes investor relations management through various communication channels, ensuring transparency and engagement with small and medium investors[98]. - The company’s profit distribution proposal requires approval from the board and shareholders, ensuring transparency and consideration of minority shareholders' opinions[151]. - The company has maintained strict compliance with its fundraising management regulations, ensuring no misuse of funds by major shareholders or actual controllers[146]. - The company has not made any adjustments to its profit distribution policy during the reporting period[152]. Product Development and Sales - The company has launched a new product, Pregabalin Oral Solution, and is actively expanding its marketing network nationwide[66]. - The revenue from the main product, Sodium Cytidine, decreased by 11.71% year-on-year, particularly in the South and Central regions, where the decline reached 30%[66]. - The company reported a decrease in gross profit margin in the South region by 3.85 percentage points, while the Northwest region saw an increase of 6.10 percentage points[65]. - The company is focusing on expanding its OTC channel and enhancing its online sales system to improve market reach[190]. - The sales model primarily involves academic promotion and distribution through third-party agencies, ensuring compliance with industry regulations[191]. - The company has seen a 27.70% increase in revenue from other products, indicating successful diversification of its product offerings[190].

公司本次以自有闲置资金购买理财产品的金额为人民币 2,000.00 万元， 截止目前，公司使用自有闲置资金购买理财产品的未到期余额为 21,894.00 万 元，占公司 2022 年度经审计净资产的 30.93%，达到上述披露标准，现予以披 露。 证券代码：832566 证券简称：梓橦宫 公告编号：2024-023 四川梓橦宫药业股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2023 年 9 月 28 日 召开第三届董事会第二十三次会议及 2023 年 10 月 20 日召开 2023 年第五次临 时股东大会，审议通过了《关于使用自有闲置资金购买理财产品的议案》。为 提高公司资金的使用效率，增加投资收益，在不影响公司主营业务的正常发展， 并确保公司正常经营需求的前提下，公司拟使用不超过人民币 35,000.00 万元 （含 35,000.00 ...